Published data from Moderna COVID-19 vaccine trial show 94.1 percent efficacy

(Brigham and Women's Hospital) Data from the COVE study, which evaluated mRNA-1273, a vaccine candidate against COVID-19 manufactured by Moderna, Inc., demonstrated 94.1 percent efficacy in preventing symptomatic COVID-19.